Cholangiocarcinoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Cholangiocarcinoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 4 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TYRA | Tyra Biosciences, Inc | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsNCT06160752Phase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200. | Phase 1 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-08-05 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| MGNX | MacroGenics | A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028 | Phase 1 | Recruiting | Nov 2026 | ≤ 102 d | 2026-04-27 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CMPX | Compass Therapeutics | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943Best Overall Response | Phase 2/3 | Active, not recruiting | 2026-12-01 | in 103 d | 2026-05-07 |
| CNTX | Context Therapeutics Inc. | CT-95 in Advanced Cancers Associated With Mesothelin ExpressionNCT06756035Determine the MTD or RD of CT-95 [Safety and Tolerability] | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-06-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Cholangiocarcinoma
most recently updated first45 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaNCT03656536results2026-08-11Randomized Treatment Period: Progression-free Survival (PFS) | Phase 3 | Terminatedsponsor's stated reason: The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision. | Drug: Pemigatinib, Gemcitabine, Cisplatin | Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma | 167 | 2019-06-03 | 2025-07-07actual | — | 2026-08-11 |
| RIGL | Rigel Pharmaceuticals | $815M | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesNCT07486713Area Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs | Phase 4 | Recruiting | Drug: Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies | 16 | 2026-02-23 | 2027-04-30 | in 253 d | 2026-08-11 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities | Phase 1 | Recruiting | Drug: LY4337713 | Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma | 241 | 2025-10-22 | Jul 2028 | ≤ 711 d | 2026-08-06 |
| TYRA | Tyra Biosciences, Inc | $1.6B | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsNCT06160752Phase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200. | Phase 1 | Active, not recruiting | Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma | 40 | 2023-11-22 | Sep 2026 | ≤ 41 d | 2026-08-05 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsNCT04521686Recommended Phase 2 Dose (RP2D) | Phase 1 | Active, not recruiting | Drug: LY3410738, Gemcitabine, Cisplatin, Durvalumab | Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor | 200 | 2020-10-01 | 2023-07-17actual | — | 2026-07-22 |
| GNFT.PA | Genfit | $805M | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaNCT05874414Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b) | Phase 1/2 | Recruiting | Drug: GNS561 + Trametinib | Cholangiocarcinoma | 98 | 2023-08-21 | Dec 2027 | ≤ 498 d | 2026-07-13 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0 | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | 2019-04-26 | Jun 2026 | — | 2026-06-23 |
| CNTX | Context Therapeutics Inc. | $49M | CT-95 in Advanced Cancers Associated With Mesothelin ExpressionNCT06756035Determine the MTD or RD of CT-95 [Safety and Tolerability] | Phase 1 | Recruiting | Drug: CT-95 | Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer | 70 | 2025-03-31 | Dec 2026 | ≤ 133 d | 2026-06-12 |
| LSTA | Lisata Therapeutics, Inc. | $10M | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsNCT05712356results2026-05-26Number of Subjects Experiencing Any Adverse Event | Phase 2 | Terminatedsponsor's stated reason: The study was halted prematurely to allow analysis of the results. | Drug: certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo | Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma | 66 | 2023-05-13 | 2026-04-05actual | — | 2026-05-26 |
| CMPX | Compass Therapeutics | $430M | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943Best Overall Response | Phase 2/3 | Active, not recruiting | Drug: CTX-009, Paclitaxel | Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer | 168 | 2023-01-09 | 2026-12-01 | in 103 d | 2026-05-07 |
| MGNX | MacroGenics | $261M | A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028 | Phase 1 | Recruiting | Biological: MGC028 | Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma | 124 | 2025-02-13 | Nov 2026 | ≤ 102 d | 2026-04-27 |
| COGT | Cogent Biosciences, Inc. | $6.4B | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsNCT06777316Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - AEs | Phase 1/2 | Active, not recruiting | Drug: CGT4859 | Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors | 110 | 2025-01-22 | Mar 2027 | ≤ 223 d | 2026-04-17 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene FusionNCT04238715ORR | Phase 2 | Completed | Drug: E7090 | Cholangiocarcinoma | 63 | 2020-01-22 | 2025-11-03actual | — | 2026-03-02 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersNCT04430738results2025-09-09Number of Participants With Renal Dose-Limiting Toxicities (DLTs): Phase 1b (Cohort 1A and 1B) | Phase 2 | Active, not recruiting | Drug: tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab | Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma | 40 | 2020-09-15 | 2024-07-31actual | — | 2026-02-24 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Drug: Felmetatug Vedotin, Pembrolizumab | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma | 250 | 2022-01-12 | 2025-05-14actual | — | 2026-01-09 |
| TCRT | Alaunos Therapeutics | $5M | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsNCT05194735results2025-11-10Number of Participants With Treatment-Emergent Adverse Events | Phase 1/2 | Terminatedsponsor's stated reason: Funding | Biological: Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2) | Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer | 8 | 2022-04-04 | 2023-08-14actual | — | 2025-11-10 |
| TLSI | TriSalus Life Sciences, Inc. | $333M | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsNCT05220722Phase 1b: To Determine the Safety of SD-101 Alone, in Combination with Pembrolizumab, and in Combination with Nivolumab and Ipilimumab | Phase 1/2 | Terminatedsponsor's stated reason: The decision was made to terminate the study after the completion of Phase 1b enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns. | Drug: SD-101 · Biological: Pembrolizumab, Nivolumab, Ipilimumab | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 23 | 2022-03-02 | 2024-07-31actual | — | 2025-10-23 |
| INCY | Incyte Corporation | $24.7B | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesNCT03144661Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB062079 | Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors | 25 | 2017-05-25 | 2020-06-10actual | — | 2025-10-21 |
| ELTX | Elicio Therapeutics | $82M | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsNCT04853017results2025-01-17The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002 | Phase 1 | Completed | Drug: ELI-002 2P | Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma | 25 | 2021-10-04 | 2023-01-26actual | — | 2025-09-05 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsNCT02784795results2025-08-21Number of Participants With LY3039478 Dose-Limiting Toxicities (DLT) in Part A, B, C, D and E | Phase 1 | Terminatedsponsor's stated reason: The study was terminated due to business considerations | Drug: LY3039478, Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414 | Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma | 94 | 2016-11-04 | 2018-08-09actual | — | 2025-08-21 |
| INCY | Incyte Corporation | $24.7B | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)NCT02924376results2023-02-23Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions | Phase 2 | Completed | Drug: Pemigatinib | Cholangiocarcinoma | 147 | 2017-01-16 | 2022-02-01actual | — | 2025-08-14 |
| TCRT | Alaunos Therapeutics | $5M | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid TumorsNCT05124743observationalNumber of Participants Positive for Human Leukocyte Antigen (HLA)-A*02 | — | Terminatedsponsor's stated reason: TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business decisions. | — | Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma, Non-small Cell Lung Cancer, Pancreas Cancer | 19 | 2021-09-24 | 2023-08-14actual | — | 2025-07-30 |
| TCRT | Alaunos Therapeutics | $5M | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRsNCT05292859observationalTo assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells | — | Completed | Biological: Neoantigen specific TCR-T cell drug product | Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer | 7 | 2023-03-01 | 2025-05-30actual | — | 2025-07-30 |
| RDHL | RedHill Biopharma Limited | — | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaNCT03377179Part1 - Determine Response Rate | Phase 2 | Completed | Drug: ABC294640, Hydroxychloroquine Sulfate 200 MG | Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic | 65 | 2018-03-07 | 2022-06-21actual | — | 2025-07-23 |
| LLY | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | $1.15T | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)NCT05432193Treatment emergent adverse events | Phase 1 | Terminatedsponsor's stated reason: Business decision | Drug: [Ga-68]-PNT6555, [Lu-177]-PNT6555 | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma | 20 | 2022-07-13 | 2023-11-10actual | — | 2025-06-25 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484Dose escalation: To determine the maximum tolerated dose of CDX-585 and to select the CDX-585 dose(s) for evaluation in tumor-specific expansion cohorts | Phase 1 | Completed | Drug: CDX-585 | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors | 20 | 2023-05-11 | 2025-05-21actual | — | 2025-06-15 |
| PFE | Pfizer | $155.3B | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding | Phase 1 | Terminatedsponsor's stated reason: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-06940434, PF-06801591 | Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer | 85 | 2019-11-13 | 2024-12-10actual | — | 2025-05-28 |
| 3402.T | Toray Industries, Inc | $12.6B | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid TumorsNCT02990481Adverse event | Phase 1 | Completed | Biological: TRK-950, TRK-950, TRK-950 | Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma | 38 | 2017-03-06 | 2019-09-16actual | — | 2025-04-16 |
| RDHL | RedHill Biopharma Limited | — | Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)NCT03414489expanded access | — | No longer available | Drug: ABC294640 | Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic | — | — | — | — | 2025-03-18 |
| INTS | Intensity Therapeutics, Inc. | $14M | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6NCT03058289results2024-08-13Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5) | Phase 1/2 | Completed | Drug: INT230-6 · Biological: anti-PD-1 antibody, anti-CTLA-4 antibody | Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma | 111 | 2017-02-09 | 2023-02-22actual | — | 2025-02-27 |
| BNTX | BioNTech SE | — | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsNCT04683939results2024-10-02Occurrence of Treatment-emergent Adverse Events (TEAEs) Within a Patient Including Grade ≥ 3, Serious, Fatal TEAE by Relationship | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BNT141, Nab-paclitaxel, Gemcitabine | Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer | 13 | 2022-01-18 | 2023-07-24actual | — | 2024-10-02 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| NXTC | NextCure, Inc. | $30M | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsNCT03665285results2024-03-08Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Completed | Drug: NC318 | Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma | 109 | 2018-10-01 | 2023-04-11actual | — | 2024-03-08 |
| MGNX | MacroGenics | $261M | A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsNCT03219268Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy) | Phase 1 | Completed | Biological: tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab | Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer | 277 | 2017-08-18 | 2023-02-08actual | — | 2023-12-21 |
| TPST | Tempest Therapeutics | $16M | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersNCT03829436Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab. | Phase 1 | Completed | Drug: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab | Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma | 38 | 2019-03-20 | 2022-09-07actual | — | 2023-07-03 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesNCT04440943Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-527 | Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors | 27 | 2020-08-04 | 2023-04-06actual | — | 2023-06-18 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2019-05-29 | 2023-02-16actual | — | 2023-03-30 |
| INCY | Incyte Corporation | $24.7B | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)NCT02393248results2023-01-06Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1/2 | Terminated | Drug: Pemigatinib, Gemcitabine, Pembrolizumab, Docetaxel, Trastuzumab, Retifanlimab, Cisplatin | Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN | 201 | 2015-02-27 | 2021-12-17actual | — | 2023-01-06 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488Determine the safety and tolerability profile of XmAb20717 | Phase 1 | Completed | Biological: XmAb20717 | Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma | 150 | 2018-07-10 | 2022-06-01actual | — | 2022-12-01 |
| DCTH | Delcath Systems Inc. | $585M | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic CholangiocarcinomaNCT02415036Objective response rate in percentage of Melphalan/HDS treatment | Phase 2 | Terminatedsponsor's stated reason: Limited enrollment | Device: Delcath Hepatic Delivery System · Drug: Melphalan | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 17 | Jun 2014 | Oct 2018actual | — | 2022-10-17 |
| DCTH | Delcath Systems Inc. | $585M | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic CholangiocarcinomaNCT03086993Overall Survival | Phase 2/3 | Unknown status | Combination product: Melphalan/HDS · Drug: Cisplatin and Gemcitabine | Bile Duct Cancer, Intrahepatic Cholangiocarcinoma | 295 | 2018-04-10 | Jan 2023 | — | 2022-03-24 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerNCT03027284Number of Participants with Merestinib Dose-Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Merestinib, Cisplatin, Gemcitabine | Advanced Cancer, Metastatic Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma, Gall Bladder Carcinoma, Solid Tumor, Non-Hodgkin's Lymphoma | 19 | 2017-02-03 | 2019-06-20actual | — | 2020-05-19 |
| HALO | Halozyme Therapeutics | $11.9B | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder AdenocarcinomaNCT03267940results2020-02-07Run-in Portion: Number of Participants With Adverse Events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: PEGPH20, CIS, GEM, Atezolizumab | Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma | 85 | 2017-10-02 | 2019-11-11actual | — | 2020-02-07 |
| ALMKT.PA | Mauna Kea Technologies | $5,661 | pCLE For the Diagnosis Of Cancer in Unknown Bile Duct StrictureNCT01392274observationalComparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l | — | Completed | — | Cholangiocarcinoma, Bile Duct Inflammation | 121 | Apr 2012 | Sep 2013actual | — | 2014-12-04 |
| ALMKT.PA | Mauna Kea Technologies | $5,661 | A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct CancersNCT00779688observationalComparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious lesions. | — | Completed | Device: Probe-based confocal laser endomicroscopy | Pancreatic Cancer, Bile Duct Cancer | 130 | Nov 2008 | Sep 2009actual | — | 2011-02-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Cholangiocarcinoma is matched — 8 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Cholangiocarcinoma
- Bile Duct Cancer
- Intrahepatic Cholangiocarcinoma
- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma, Extrahepatic
- Cholangiocarcinoma, Intrahepatic
- Cholangiocarcinoma, Perihilar
- Metastatic Cholangiocarcinoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Cholangiocarcinoma” (a text search, wider than this page)